Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a "novel transcript" that is antisense to the METTL2B gene (Methyltransferase like 2B), based on its Ensembl identifier ENSG00000302221. There is no evidence that this transcript encodes a functional protein, nor is it classified as a therapeutic target such as a receptor, enzyme, transporter, or ion channel. The designation suggests an uncharacterized non-coding RNA running in the opposite genomic direction to the METTL2B gene. There are currently no data on its biological function, molecular pathway, disease involvement, drug interactions, or clinical utility. For information on METTL2B itself, refer to canonical entry for N3-methylcytidine methyltransferase 2B, a tRNA-modifying methyltransferase with some emerging evidence of a role in cancer biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to METTL2B.